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ABSTRACT
DPF3 (BAF45c) is a member of the BAF chromatin
remodeling complex. Two isoforms have been de-
scribed, namely DPF3a and DPF3b. The latter binds
to acetylated and methylated lysine residues of his-
tones. Here, we elaborate on the role of DPF3a and
describe a novel pathway of cardiac gene transcrip-
tion leading to pathological cardiac hypertrophy.
Upon hypertrophic stimuli, casein kinase 2 phospho-
rylates DPF3a at serine 348. This initiates the inter-
action of DPF3a with the transcriptional repressors
HEY, followed by the release of HEY from the DNA.
Moreover, BRG1 is bound by DPF3a, and is thus re-
cruited to HEY genomic targets upon interaction of
the two components. Consequently, the transcription
of downstream targets such as NPPA and GATA4
is initiated and pathological cardiac hypertrophy is
established. In human, DPF3a is significantly up-
regulated in hypertrophic hearts of patients with hy-
pertrophic cardiomyopathy or aortic stenosis. Taken
together, we show that activation of DPF3a upon hy-
pertrophic stimuli switches cardiac fetal gene ex-
pression from being silenced by HEY to being ac-
tivated by BRG1. Thus, we present a novel pathway
for pathological cardiac hypertrophy, whose inhibi-
tion is a long-term therapeutic goal for the treatment
of the course of heart failure.
INTRODUCTION
Cardiac hypertrophy is defined as the increase in myocar-
dial mass in response to pressure or volume stress, or muta-
tions of sarcomeric proteins (1). Pathological hypertrophy
represents a key risk factor for heart failure and accompa-
nies nearly all forms of cardiovascular disease, including hy-
pertension, hypertrophic cardiomyopathy (HCM) and aor-
tic stenosis (AS). Sustained hypertrophy, which can eventu-
ally lead to heart failure, is associated with increased inter-
stitial fibrosis, cell death and contractile dysfunction (2–4).
Therefore, the prevention of pathological hypertrophy is of
great therapeutic interest for cardiovascular disease.
On the cellular level, cardiac hypertrophy is characterized
by an increase in cardiomyocyte size, with enhanced protein
synthesis and changes to the sarcomere organization (5).
Pathological stress is mediated via several intracellular sig-
naling pathways that eventually activate the fetal gene pro-
gram. The casein kinase 2 (CK2)-mediated signaling cas-
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cades have been shown to be important for the development
of cardiac hypertrophy. CK2 is a typical serine/threonine
kinase consisting of two catalytic subunits (, ’ or ’’)
as well as two regulatory  subunits and has been impli-
cated in many cellular and developmental processes (6).
CK2’, one of the catalytic subunits, is activated by the car-
diac growth factor angiotensin II, which results in an imbal-
anced feedback loop between p27 and CK2’ that is crucial
for agonist- and stress-induced cardiac hypertrophic growth
(7). Knockout of the other catalytic subunit CK2 in mice
leads to structural defects in the heart and somites, with
mice dying inmid-gestation (8). In response to hypertrophic
stimuli, CK2 translocates to the nucleus and activates hi-
stone deacetylase 2 (HDAC2) by phosphorylating HDAC2
at serine 394 (9).
Cardiac hypertrophy is accompanied by up-regulation of
the fetal gene program. Fetal genes are a set of genes that
are often expressed only in the developing heart and are
re-expressed during cardiac hypertrophy, and include na-
triuretic peptides (NPPA, NPPB), structure proteins (β-
MHC, α-skeletal actin) and others (5). Transcriptional re-
programming of gene expression and reactivation of fetal
genes are tightly controlled by transcription factors as well
as chromatin modifying and remodeling factors (10–12).
The chromatin remodeling complexes alter chromatin
structure using the free energy of ATP hydrolysis to change
nucleosome positions relative to theDNA. Themammalian
SWI/SNF-like complex (BAF complex) consists of 9–12
components, including the core component encoded by ei-
ther brahma (BRM) or brahma-related gene 1 (BRG1)
(13). Depletion of myocardial BRG1 causes a thin, com-
pact myocardium and absent interventricular septum, and
leads to embryonic lethality. In embryonic cardiomyocytes,
BRG1 forms a complex with poly (ADP-ribose) poly-
merases (PARPs) to activate the fetal gene beta-myosin
heavy chain (β-MHC), while it represses the cardiac con-
tractile protein alpha-myosin heavy chain (α-MHC) via in-
teraction with HDACs. Normally, BRG1 is turned off in
the adult heart, but when the heart is stressed by disease or
pressure overload, BRG1 is reactivated and interacts with
HDACs and PARPs to repress α-MHC and activate β-
MHC expression (14). A recent study showed that Mhrt,
a cardiac specific long non-coding RNA, protects the heart
from pathological hypertrophy via binding to BRG1, and
thereby inhibiting chromatin targeting and gene regulation
(15). Another muscle-specific component of the BAF com-
plex is BAF60c (encoded by SMARCD3), which is highly
expressed in heart and skeletal muscle during development
(16). In skeletal muscle differentiation, phosphorylation
of BAF60c by the p38 kinase promotes MyoD-BAF60c
binding into the BAF complex, and thereby remodels chro-
matin and activates transcription ofmyogenic genes (17,18).
In 2008, we identified DPF3 (also named BAF45c) as
a novel epigenetic factor for heart and muscle develop-
ment. DPF3 is significantly up-regulated in patients with
Tetralogy of Fallot (TOF), which is characterized by struc-
tural cardiac defects and right ventricular hypertrophy
(19,20). Morpholino knockdown of dpf3 in zebrafish leads
to impaired skeletal and cardiac muscle development and
severely reduced ventricular contractility, with disassem-
bled muscular fibers caused by transcriptional deregulation
of structural and regulatory proteins (20). DPF3 consists of
two distinct isoforms, namely DPF3a and DPF3b. The lat-
ter contains two plant homeodomains (PHD) that can bind
to methylated and acetylated lysine residues of histone H3
and H4 (20), enabling a regulatory switch between poised
and activated chromatin stages (21).
Here, we aim to shed light on the function of DPF3a,
which is characterized by a half PHDfinger and a specificC-
terminus of so far unknown function. We show that DPF3,
in particular DPF3a, is significantly up-regulated in patho-
logic cardiac hypertrophy in patients with HCM as well as
AS. In response to hypertrophic stimuli, the protein kinase
CK2 phosphorylates DPF3a that consequently binds and
releases the transcriptional repressors HEY and recruits
BRG1 to respective targets. Consequently, phosphorylated
DPF3a (pDPF3a) initiates transcription of fetal genes pro-
moting cardiac hypertrophy.
MATERIALS AND METHODS
Human samples
All cardiac samples were obtained with the approval of
the ethics committee of the Charite´ – Universita¨tsmedizin
Berlin and written informed consent was obtained for all
individuals. Excised cardiac tissue from the left ventricular
outflow tract was used in the study. It was obtained from
four unrelated patients with AS undergoing aortic valve re-
placement, and from eight unrelated patients with HCM
and severe obstruction of the left ventricular outflow tract
undergoing transaortic subvalvular myotomy–myectomy.
Both patient groups were characterized by severe hypertro-
phy of the left ventricle. Tissue from normal human hearts
was obtained from unmatched organ donors without car-
diac disease. All samples were snap frozen in liquid nitro-
gen after excision and stored at −80◦C. Paraffin embedded
TOF and normal heart samples were obtained as previously
described (22).
Human-induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs)
The human-induced pluripotent stem cell line derived from
a healthy individual was generously provided by the Stem
Cell Core Facility of the Berlin Institute of Health (BIH).
Cardiomyocyte differentiation was mediated by modulat-
ingWnt-signaling, applying small molecules under fully de-
fined conditions (23,24). Briefly, iPSCs were maintained in
Essential 8 Media (Gibco) on Geltrex (Gibco) 6-well plates.
iPSCs were dissociated using an EDTA-based passaging
procedure (25) and 0.2–0.4 million cells were seeded in one
12-well plate containing Essential 8 media supplemented
with 5 M Pro-survival Compound, DDD00033325 (Cal-
biochem). After 24 h, Essential 8 media was exchanged and
cells were maintained for an additional 24 h.
At day 0, differentiation was induced using RPMI/B27
without insulin supplemented with 9 M GSK-3 inhibitor
XVI (Calbiochem). Exactly 24 h later, media was changed
to RPMI/B27 without insulin, and cells were subsequently
cultivated for 48 h. On day 3, the differentiation media was
exchanged for RPMI/B27 without insulin supplemented
with 5 M IWP2 (Calbiochem), and cells were cultivated
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for an additional 48 h. The media was then changed back
to RPMI/B27 without insulin on day 5 of differentiation.
From day 7 onwards, cells were cultivated in RPMI/B27
and media was exchanged every 3 days.
Flow cytometry
After 15 days of differentiation, cells were washed twice
with pre-warmed PBS and were singularized by applying
0.25% Trypsin/EDTA. Cells were fixed with 1% formalde-
hyde for 20 min at room temperature and were permealized
using 90% ice-cold methanol and were subsequently stored
at −20◦C. For evaluation of differentiation efficiency, 105
cells were evaluated. Briefly, cells were washed twice in PBS
with 0.5% BSA (Flow Buffer 1) and incubated with the pri-
mary antibody against cardiac Troponin T (mouse IgG1,
Lab Vision; 1:500) in PBS with 0.5% BSA and 0.1% Triton-
X (Flow Buffer 2) at 4◦C overnight. Afterwards, cells were
washed with Flow Buffer 1 and were incubated with the
secondary antibody Goat anti-Mouse IgG1 conjugated to
Alexa Fluor 488 (1:1000) for 30 min at room temperature.
Samples were washed twice with Flow Buffer 1 and were fil-
tered through a 50 m filter and evaluated on a BD FACS
Canto II.
Metabolic selection of hiPSC-CMs
As the analyzed population showed only an insufficient pu-
rity of 78% iPS-CMs metabolic purification applying lac-
tate was performed as previously described (26). Briefly,
cells were reseeded in lower density in RPMI supplemented
with insulin, 20%Fetal Bovine Serum (FBS) and 5MPro-
survival Compound, DDD00033325 (Calbiochem) by ap-
plying 0.25% Trypsin/EDTA. Cells were allowed to recover
for 4 days and were then cultivated in RPMI without Glu-
cose and HEPES supplemented with 4 mM Sodium DL-
lactate solution (Sigma) for 4 days. Afterwards, media was
changed back to RPMI with insulin. All subsequent analy-
ses were performed at a cell density of 37 500 cells/cm2.
Cell culture
C2C12 myoblasts, H9C2 cardiomyocytes and HEK293T
cells were cultured at 5% CO2 and 37◦C in Dulbecco’s
Modified Eagle’s Medium (Gibco) supplemented with 1%
penicillin/streptomycin (Gibco) and 10% FBS (Biochrom).
HL-1 cells were cultured in Claycomb medium (Sigma)
containing 10% FBS, 100 mM norepinephrine, 4 mM L-
glutamine and 1% penicillin/streptomycin.
For phenylephrine (PE) or Edothelin 1 (ET-1) treatment,
HL-1, H9C2 or hiPSC-CMswere incubated with 10MPE
(Sigma) or 1 nM ET-1 for 24 h. Cells were then harvested
for RNA isolation or fixed with methanol for immunofluo-
rescence staining.
Isolation and transfection of mouse primary cardiomyocytes
Neonatal hearts were isolated from 1–3 days old mice. Af-
ter removing atria and large arteries, ventricles were minced
and treated with collagenase buffer for 1 h at room tempera-
ture with gently shaking. The enzyme digestionwas stopped
by the addition of 10% FBS containing DMEM. Fibrob-
lasts were removed twice by 1 h pre-plating. The cardiomy-
ocytes were counted and plated on collagen-coated culture
dishes and were maintained in 10%FBS inDMEMwithout
antibiotics. Isolated mouse primary cardiomyocytes were
cultured for 3 days and then transfected with Flag-tagged
DPF3a WT and S348A mutant constructs using Lipofect-
mine 3000 (Invitrogen).
Recombinant protein expression and purification
GST fusion proteins were expressed in E. coli BL21 DE3
pRARE3 and purified usingGlutathione–Sepharosematrix
(GE Healthcare) according to the manufacturer’s instruc-
tions.
GST pull-down
GST-CK2/’/ fusion proteins were coupled to
Glutathione–Sephharose matrix, according to the manu-
facturer’s indication (GE Healthcare), and subsequently
incubated with Flag-DPF3a/b recombinant proteins for
2 h at 4◦C in binding buffer (4.2 mM Na2HPO4, 2 mM
KH2PO4, 250 mM NaCl, 10 mM KCl, 0.1% NP40, 0.5%
BSA, pH 7.2, complete protease inhibitor (Roche)). Matri-
ces were washed three times in binding buffer, resuspended
in 4x LDS sample buffer, denatured at 95◦C for 5 min and
subjected to Western blot analysis.
Phosphorylation prediction and conservation analysis of
DPF3a
The multiple alignment of DPF3a in different species was
generated using ClustalW2 (27). Phosphorylation site pre-
diction was performed using NetPhos 2.0 Server (28) with
standard parameters. CK2-specific phosphorylation site
prediction was carried out using KinasePhos 2.0 (29) with
standard parameters.
Mass spectrometry analysis
Tandem affinity purification followed by mass spectrome-
try was carried out as described previously (20). To study
the phosphorylation of DPF3a, HEK293T cells were trans-
fected with Flag-DPF3a. Cell extracts were immunoprecip-
itated with anti-Flag M2 antibody (Sigma) and immuno-
precipitated complexes were digested in solution. Phospho-
peptide enrichment was conducted using the Titansphere
Phos-TiO kit (GLSciences).Mass spectrometry analysis for
identification of proteins and for detection of protein phos-
phorylation was performed as previously described (30,31).
In vitro kinase assay
In vitro phosphorylation of recombinant proteins was per-
formed as described previously (32). Briefly, 1g ofGST fu-
sion proteins were incubated with recombinant active CK2
(NEB) and ATPS (Epitomics) in the reaction buffer at
30◦C for 2 h. Proteins were then alkylated with 2.5 mM p-
Nitrobenzyl mesylate (PNBM, Epitomics) for 2 h at room
temperature and the products were analyzed by Western
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blot using an anti-Thiophosphate ester antibody (Epito-
mics). The CK2-specific inhibitor tetrabomocinnamic acid
(TBCA, Millipore) was used to abolish CK2 activity in the
in vitro kinase assay.
Generation of anti-pDPF3a antibody
The DPF3a antibody that can specifically recognize phos-
phorylated S348 (anti-pDPF3a) was generated in rabbit
by Thermo Fisher Scientific. The phosphorylated peptide
against the epitope CRRSGRG[pS]PTADK of DPF3a was
used.
Co-immunoprecipitation (CoIP)
HEK293T cells were transiently transfected with the indi-
cated expression vectors for Flag- or HA-tagged proteins
using polyethylenimine (PEI). The cells were lysed in CoIP
buffer (20 mM Tris-HCl pH 7.4, 150 nM NaCl, 1 mM
EDTA, 1% Triton, 1 mM DTT, 0.1 mM PMSF, 1 mM
NaVO4, protease inhibitor (Roche) and phosphatase in-
hibitor (Roche)). Protein concentrations were determined
using the Bradford assay (Sigma). A total of 500 g cell ex-
tracts were incubated with Flag M2 matrix (Sigma) or HA-
matrix (Roche) for 2 h at 4◦C. The matrix was then washed
three times with ice-cold CoIP buffer and eluted forWestern
blot.
Western blotting and quantification
Cells and human cardiac biopsies were treated with lysis
buffer (20 mM Tris-HCl pH 7.4, 150 nM NaCl, 1 mM
EDTA, 1% Triton, 1 mM DTT, 0.1 mM PMSF, protease
inhibitor (Roche), 1 mM NaVO4) for protein extraction.
Western blot was performed according to standard proto-
cols. All antibodies, with their respective dilutions, are given
in Supplementary Table S1. Image Lab 5.0 (Bio-Rad) was
used to quantify the blot signals.
Immunofluorescence staining
For cell immunofluorescence analysis, the cells were fixed
withmethanol. Blocking was carried out in 3% normal goat
serum in PBS for 1 h at room temperature. Primary and sec-
ondary antibodies were applied in the same buffer for 2 h at
room temperature, each followed by three washes in PBS
and a DAPI counterstaining. The cells were mounted in
Mowiol 4–88 (Carl Roth) and examined on a LSM 710 con-
focal microscope (Carl Zeiss). The cell size of transfected
cells was measured using ImageJ.
For human tissue immunofluorescence analysis, paraffin-
embedded right ventricular biopsies of healthy and TOF in-
dividuals were rehydrated and subjected to heat-mediated
antigen retrieval and quenching of endogenous peroxidase
activity. Blocking was performed with donkey serum (10%)
and BSA (2%) in PBT (0.3%) and primary antibodies were
applied overnight at 4◦C in the same buffer. Correspond-
ing secondary antibodies were subsequently applied, and
the tissue incubated for 1 h at room temperature; this was
followed by application of Vectastain Elite ABC Kit (Vec-
tor Lab) and TSA Plus Cyanine-5 System (Perkin Elmer)
according to the manufacturer’s instructions. Nuclei were
counterstained with DAPI and slides mounted with Flu-
oromount (Sigma). Omission of the first antibody served
as a negative control. All images were captured using a Le-
ica SP5 confocal microscope. Antibodies and reagents with
their respective dilutions are listed in Supplementary Table
S1.
RNAi knockdown
For RNAi knockdown, C2C12 cells or hiPSC-CMs were
transfected with siRNAs (Supplementary Table S2) target-
ing Dpf3a, Hey1 and Ck2α, respectively. As a control, the
cells were transfected with an unspecific siRNA (siNon).
Cells were grown to 50% confluence for at least 2 days with-
out addition of antibiotics. A total of 1 × 105 cells were
seeded into 6-well plates with 2 ml media resulting in 40%
confluence after 4 h. The mixture of 4.4 l (20 M) siRNA
in 100 l of DMEM media and 8.8 l Lipofectamine 3000
(Invitrogen) in 100 l DMEM media was incubated for 15
min at room temperature and added drop-wise to the cells.
The cell culture medium was changed after 24 h and cells
were harvested for protein extraction or RNA preparation
after 48 h.
Gene expression analysis
Total RNA of cultured cells and human cardiac biopsies
was isolated using TRIzol reagent (Invitrogen) followed by
DNase digest (Promega) and ethanol precipitation accord-
ing to standard protocols. Reverse transcription reactions
were carried out via AMV-RT (Promega) with random hex-
amers (Amersham Pharmacia Biotech). Quantitative real-
time PCR measurements were performed using the Go-
Taq qPCR Master Mix (Promega) and the ABI PRISM
7900HT Sequence Detection System. Gene expression was
calculated using theCTmethodwith normalization to the
housekeeping gene HPRT or GAPDH. Primer sequences
are given in Supplementary Table S3.
Chromatin immunoprecipitation (ChIP) and qPCR
ChIP experiments with C2C12 cells were carried out with
the MAGnifyTM Chromatin Immunoprecipitation System
(Life Technologies) following the manufacturer’s instruc-
tions with some modifications. Sonication was performed
using the Bioruptor UCD300 (Diagenode) to obtain chro-
matin fragments of approximately 100–500 bp. For Hey1
ChIP, C2C12 cells were transiently transfected with Flag-
Hey1 and empty Flag vector, which was used as a con-
trol. Anti-pDPF3a and anti-Flag M2 antibodies were used
in ChIP experiments. ChIP DNA was purified using the
Zymo ChIP DNA cleanup kit. ChIP results were analyzed
by quantitative PCR. ChIP enrichment was normalized to
the input and expressed as relative enrichment of the mate-
rial precipitated by the indicated antibody on target regions.
ChIP primers are listed in Supplementary Table S4.
Site-directed mutagenesis
Site-directed mutagenesis of DNA was performed using
the QuikChange II site-directed mutagenesis kit (Agilent)
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according to manufacturer’s instructions. Oligonucleotides
formutagenesis were designed to introducemutations of the
DPF3a phosphorylation sites. Mutagenesis was confirmed
by plasmid sequencing (Eurofins Genomics).
Reporter gene assay
For luciferase assays, approximately 104 HEK293 cells were
transiently transfected with 50 ng of reporter vector, 5 ng
of Renilla luciferase vector for internal normalization of
transfection efficiency and 50–150 ng of the respective ex-
pression vectors. Activity wasmeasured byDual-Luciferase
assay (Promega) after 48 h in a Centro LB960 Luminome-
ter (Berthold, Bad Wildbad, Germany). All measurements
were performed in triplicates.
RESULTS
DPF3 is significantly up-regulated in hypertrophic hearts
In mammals, DPF3 occurs in two splice variants, namely
DPF3a and DPF3b. DPF3a (BAF45c1) is characterized
by a functionally unknown half PHD finger followed by a
unique C-terminus, whereas DPF3b (BAF45c2) comprises
a C-terminus harboring a double PHD finger previously
characterized by us and others (Figure 1A) (20,21). Both
variants are expressed in all four chambers of the normal
human adult hearts with DPF3a being continuously higher
expressed than DPF3b (Figure 1B).
Previously, we showed that both DPF3a and DPF3b are
significantly up-regulated in the hypertrophic right ventri-
cle of TOF hearts (19,20). To further investigate the role
of DPF3 in pathological cardiac hypertrophy, we studied
cases of HCM and pressure overload related hypertrophy
resulting from AS. The details of all human heart sam-
ples are given in Supplementary Table S5. Quantitative real-
time PCR showed a significant up-regulation of DPF3 as
well as the two individual splice variants in the left ven-
tricle of HCM and AS cases compared to normal hearts
(NH) (P < 0.05; Figure 1, C and D). Pathological cardiac
hypertrophy is regulated by re-activation of fetal gene ex-
pression. To test if DPF3 is a fetal-like gene, we analyzed
the expression ofDPF3a and DPF3b during differentiation
of human-induced pluripotent stem cell-derived cardiomy-
ocytes (hiPSC-CMs). The differentiation process and purity
of hiPSC-CMs was characterized by marker gene analysis
and flow cytometry (Supplementary Figure S1). Interest-
ingly, DPF3a shows a similar expression profile to the fetal
gene NPPA with the highest expression at day 10, whereas
DPF3b is expressed at a very low level during the differen-
tiation process (Figure 1E). Taken together, all these results
suggest that DPF3a can be considered as a fetal-like gene,
which might play a role in pathological cardiac hypertrophy
in general.
CK2 binds and in vitro phosphorylates DPF3a
To elucidate the role of DPF3 in cardiac hypertrophy, we
first searched for DPF3 interacting proteins in HEK293
cells. Using the tandem affinity purification (TAP) tech-
nique followed by mass spectrometry (MS) analysis, we
identified 11 and 6 proteins specifically interacting with
DPF3a or DPF3b, respectively, with a Mascot score >40
and a minimum number of two matching spectra (Table
1). All subunits of the tetrameric casein kinase 2 complex,
CK2, CK2’ and CK2 were found as exclusive interac-
tion partners ofDPF3a (Table 1).None of theCK2 subunits
was identified when DPF3b was used as the bait protein.
This observation led us to investigate whether DPF3a
could directly associate with CK2/’/ in vitro. Thus, we
performed in vitro interaction studies with purified pro-
teins, using GST-tagged purified CK2/’/ in combina-
tion with Flag-tagged DPF3a/b. Pull-down assays showed
that DPF3a strongly interacts with CK2 and weakly binds
to CK2 (Figure 2A). This is in line with the fact that CK2
is the catalytic subunit, whereas CK2 is the regulatory sub-
unit of CK2 and responsible for substrate recognition (6).
Again, we observed no interactions between CK2 subunits
andDPF3b (Figure 2A). CK2 is a well-known ubiquitously
expressed and evolutionarily conserved serine/threonine
protein kinase (6). To investigate whether DPF3a is phos-
phorylated by CK2, we applied in vitro kinase assays using
purified GST-fusion protein of DPF3a, with GST-DPF3b
and GST-NEP serving as negative and positive control, re-
spectively (33). BothDPF3a andNEP, but notDPF3b, were
in vitro phosphorylated by CK2 and DPF3a phosphoryla-
tion became saturated when 500U CK2 was applied in the
kinase assay (Figure 2B). Moreover, DPF3a phosphoryla-
tion is reduced upon treatment with increasing amounts of
the CK2 specific inhibitor TBCA (Figure 2C), indicating
that DPF3a phosphorylation in vitro is largely dependent
on CK2 activity.
S348 of DPF3a is phosphorylated by CK2 in vivo
In order to analyze which residues of DPF3a are phospho-
rylated by CK2, we used the prediction tools Netphos 2.0
(28) andKinasePhos 2.0 (29). We found potential phospho-
rylation sites for the full DPF3a sequence and revealed sev-
eral sites in the DPF3a-specific C-terminus. Here, multiple
minimal CK2 consensus motifs (S/T-X-X-E/D) were pre-
dicted between aa293 and aa357 (T309, T310, S316, S318
and S348) (Supplementary Figure S2). The DPF3a specific
C-terminus is highly conserved across vertebrate and mam-
malian species (Supplementary Figure S3). To confirm po-
tential phosphorylation sites, we analyzed the phosphoryla-
tion of DPF3a in HEK293 cells using immunoprecipitation
followed by mass spectrometry analysis. In total, we iden-
tified three phosphorylation sites in DPF3a, namely S138,
S348 and T350 (Table 2). Of these, in particular S348 is con-
served in human, mouse and chicken (Figure 2D), which
suggests a potential functional role of this site. Therefore,
we studied the CK2 dependent phosphorylation of DPF3a
S348 using an in vitro kinase assay on purified GST-fusion
protein in which serine 348 wasmutated to alanine (S348A).
We found that phosphorylation of DPF3a by CK2 is signif-
icantly reduced by the mutation of S348A compared to the
wild-type (WT) DPF3a (Figure 2E). We also mutated all
five predicted CK2 mediated phosphorylation sites (5xAla)
and observed a further reduction of DPF3a phosphoryla-
tion (Figure 2E), suggesting additional functional phospho-
rylation sites in vitro.
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Figure 1. Up-regulation of DPF3 in hypertrophic hearts. (A) Schematic representation of the DPF3 isoforms. The isoform DPF3a contains a half PHD
finger and a specific C-terminus, whereas DPF3b contains a double PHD finger. Amino acid positions are depicted. Teal: 2/3 domain; green: C2H2-
Kru¨ppel-like zinc finger; orange: first plant homeodomain; blue: second plant homeodomain; red: DPF3a specific C-terminus. (B) Expression analysis of
DPF3a andDPF3b splice variants in normal human heart tissues (n = 4) of left ventricle (LV), right ventricle (RV), left atrium (LA) and right atrium (RA)
using qPCR. Results represent median expression levels with 25% and 75% quartile; assays were performed in triplicates. (C) Expression of DPF3mRNA
in hypertrophic and healthy hearts. qPCR analysis of DPF3 mRNA levels in myocardial, left ventricular tissue from patients with aortic stenosis (AS),
hypertrophic cardiomyopathy (HCM) and normal hearts (NH). (D) Analysis of splice variants expression of DPF3a and DPF3b in AS, HCM and NH.
Statistically significant differences were analyzed using a two-sided Student t-test (*P < 0.05). (E) Temporal expression profiles of DPF3a, DPF3b and
NPPA during differentiation of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). qPCR was performed on samples obtained
from different days during cardiac differentiation. Expression values were normalized to the housekeeping gene GAPDH.
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Table 1. DPF3a and DPF3b specific interaction partners in cytoplasm
Bait
protein Hugo ID
Accession
number MW (Da)
Mascot
score
Matching
spectra Protein name
DPF3a CSNK2A1 P68400 45 229 459 13 Casein kinase II subunit alpha
CSNK2A2 P19784 41 358 251 10 Casein kinase II subunit alpha’
CSNK2B P67870 25 268 54 5 Casein kinase II subunit beta
ASCC3L1 O75643 246 006 56 3 activating signal cointegrator 1 complex subunit 3-like 1
UBR4 Q5T4S7 580 547 49 8 Zinc finger UBR1-type protein 1, ubiquitin protein ligase E3 component n-recognin 4
UBR5 O95071 312 352 49 5 E3 ubiquitin-protein ligase EDD1
HDGFRP3 Q9Y3E1 22 663 101 3 Hepatoma-derived growth factor-related protein 3
HSPA1L P34931 70 730 71 6 Heat shock 70 kDa protein 1L
AIFM1 O95831 67 144 41 4 Apoptosis-inducing factor 1, mitochondrial precursor
IGKC P01834 11 773 61 2 Ig kappa chain C region
GPSN2 Q9NZ01 36 410 51 4 Synaptic glycoprotein SC2
DPF3b TUBA8 Q9NY65 50 746 75 9 Tubulin alpha-8 chain
XPOT O43592 111 148 41 5 Exportin-T
TUBA3E Q6PEY2 50 626 444 13 Tubulin alpha-3E chain
EEF1A2 Q05639 50 780 51 3 Elongation factor 1-alpha 2
TIMM50 Q3ZCQ8 39 850 143 3 Import inner membrane translocase subunit TIM50, mitochondrial precursor
AHSA1 O95433 38 421 48 2 Activator of 90 kDa heat shock protein ATPase homolog 1
Protein specifically associated with DPF3a or DPF3b in the cytoplasm identified by tandem affinity purification followed by mass spectrometry. Da: Dalton, MW: molecular weight.
Table 2. Phosphorylated sites in DPF3a
Peptide Mascot score PEP Position
EEES(ph)IQEIQR 171.99 2.08E-05 138
GS(ph)PTADKK 108.43 2.05E-06 348
GSPT(ph)ADKK 130.66 1.83E-11 350
Phosphorylated sites within DPF3a identified by mass spectrometric analysis. PEP: posterior error probabilities.
Furthermore, we generated a DPF3a antibody that can
specifically recognize phosphorylated S348 (anti-pDPF3a).
The specificity of the anti-pDPF3a antibody was confirmed
byWestern blot and immunofluorescence with peptide con-
trol assays (Supplementary Figure S4). In immunofluores-
cence staining, we found that pDpf3a is exclusively present
in the nucleus in HL1 and C2C12 cells (Supplementary Fig-
ure S4, Figure 2I). Further, we could verify the in vitro phos-
phorylation of Dpf3a S348 by Ck2 using the anti-pDPF3a
antibody (Figure 2F). In order to investigate phosphory-
lation of S348 in vivo, we knocked down Ck2 using RNA
interference in C2C12 myoblasts. Treatment with siCk2
significantly reduced Ck2 mRNA and protein expression
(Figure 2, G and H). Elimination of Ck2 function did not
affect the expression of Dpf3a (Figure 2G). Notably, the
phosphorylation of DPF3a at S348 was abolished in Ck2
knockdown (Figure 2, H and I), suggesting that S348 is in
vivo phosphorylated by Ck2.
Phosphorylation of S348 is essential for cardiac hypertrophy
Considering a previous report showing activation and
translocation of Ck2 upon hypertrophic stimuli (9), we
investigated this pathway with respect to Dpf3a and ex-
amined whether hypertrophic stimuli induce phosphory-
lation of DPF3a mediated by Ck2. We induced hyper-
trophic stress in mouse HL1, rat H9C2 cells as well as
hiPSC-CMs using 10 M phenylephrine (PE). The expres-
sion of Nppa, a marker of hypertrophy, increased in HL1
and H9C2 cells upon PE treatment (Supplementary Figure
S5A). PE stimulation significantly increased the mRNA ex-
pression (Supplementary Figure S5A) and the phosphory-
lation of Dpf3a in both HL1 and H9C2 cells (Supplemen-
tary Figure S5B). During differentiation of hiPSC-CMs, the
protein level of pDPF3a increased on day 5 and remained
stable thereafter (Supplementary Figure S5C). In line with
another publication (34), hiPSC-CMs did not respond to
PE with unchanged NPPA expression (Figure 3A). How-
ever, endothelin 1 (ET-1) treatment successfully increased
NPPA and DPF3a expression in hiPSC-CMs (Figure 3A).
DPF3a phosphorylation was significantly increased upon
ET-1 stimulation (Figure 3B).Moreover, we observedmuch
higher levels ofDPF3a phosphorylation in hypertrophic left
ventricle of patients with HCM and AS compared to NH
hearts (Figure 3C). In addition, many more pDPF3a pos-
itive cells were found in the hypertrophic right ventricle of
TOF hearts compared to NH hearts (Figure 3D). Further-
more, knockdown of DPF3 in hiPSC-CMs decreased the
increment of NPPA expression in the ET-1 situation (Fig-
ure 3E), suggesting that ET-1 induced hypertrophy can be
buffered by the abolition of DPF3. To further investigate
whether S348 phosphorylation is required for hypertrophy,
mouse primary cardiomyocytes were transfected with Flag-
tagged WT DPF3a or S348A mutant constructs (Figure
3F). Non-transfected cells were used as controls and stained
for cell size measurements. Overexpression of DPF3a WT
increased cell size and Nppa expression, whereas cell size
changes and Nppa expression alterations could not be ob-
served in those transfected with the S348A mutant con-
structs (Figure 3, G and H), indicating that the phospho-
rylation of S348 is required for the hypertrophic response.
DPF3a interacts with the transcription repressors HEY
To identify downstream targets of DPF3a, we performed
protein binding microarray (PBM) and ChIP-seq anal-
ysis. In the PBM experiments, a purified GST-tagged
DPF3a or DPF3b protein was applied to a ‘universal’
PBM representing all 10 bp double-stranded DNA (ds-
DNA) sequences (35). Neither DPF3a nor DPF3b exhib-
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Figure 2. CK2 binds and phosphorylates DPF3a at S348. (A) GST pull-down with GST-CK2 subunits and Flag-DPF3a/b. Similar expression of GST
levels could be shown for the CK2 subunits and the control GST vector. GST pull-down results show an interaction of the CK2 and  subunit with
full-length DPF3a. (B) In vitro CK2 kinase assay with recombinant CK2 and purified GST fusion DPF3a. Increasing amount of CK2 was incubated
with GST-DPF3a and combinations of ATPS and p-nitrobenzyl mesylate (PNBM) as indicated; reaction products were analyzed by Western blot with
anti-Thiophosphate ester antibody. GST-DPF3b and GST-NEP were used as the negative and positive control, respectively. Immunoblotting against GST
demonstrates that a similar amount of protein was used for each condition. (C) The CK2 specific inhibitor, tetrabromocinnamic acid (TBCA), was used in
the kinase assay and effectively reducedDPF3 phosphorylation. (D) Sequence conservation of DPF3a peptides surrounding the identified phosphorylation
sites in human, mouse, rat and chicken. (E) GST-DPF3a WT, S348A mutant or 5xAla mutant were in vitro phosphorylated by CK2 before blotting. (F)
GST-DPF3a was phosphorylated by CK2 and detected using the anti-pDPF3a antibody in immunoblotting. (G) Knockdown of Ck2 in C2C12 cells
using siRNA. Expression of Ck2α andDpf3a after Ck2 siRNA knockdown was analyzed by qPCR. (H) The protein level of Ck2 and pDPF3a was was
analyzed by immunoblotting in Ck2 knockdown situation. (I) Immunofluorescence analysis of pDPF3a in Ck2 knockdown situation in C2C12 cells.
C2C12 cells were transfected with Ck2 siRNA for 48 h. The cells were then fixed with methanol and stained with antibody against pDPF3a (red) and
antibody against Tubulin (green). Scale bar, 20 m.
ited sequence-specific binding to dsDNA (data not shown).
However, previously we found several hundred sites of indi-
rect DNA binding using ChIP-chip. For DPF3b, we could
show that this binding is mediated by specific histone marks
(20). Focusing on pDPF3a, we now identified approxi-
mately 800 binding sites in ChIP-seq experiments using
undifferentiated and differentiated C2C12 cells (data not
shown). Using a pattern matching approach, we found that
the E-box motif, which represents the favored binding mo-
tif of basic helix-loop-helix (bHLH) transcription factors,
is highly enriched in pDPF3a target sites (Supplementary
Table S6).
bHLH transcription factors, such as HAND1/2,
MYOD1, HES1 and HEY1/2, are important for em-
bryonic development with respect to cardiac and muscle
development. In order to study the interaction of DPF3a
with these bHLH transcription factors (MYOD1,HAND1,
HES1 andHEY1), we performedCoIP analysis with lysates
of transiently transfected HEK293 cells. We observed a
specific interaction between DPF3a and HEY1, the hairy
and enhancer of split-related family of bHLH-type tran-
scriptional repressors (Figure 4A). HEY genes redundantly
function during mouse embryonic cardiovascular devel-
opment, neurogenesis and somitogenesis (36), and thus
match the expression and proposed function of DPF3a.
Finally, we found that all proteins of the HEY family,
namely HEY1, HEY2 and HEYL, specifically interact
with DPF3a (Supplementary Figure S6A). In the following
study, we exclusively focus on HEY1 as an example to
analyze the function of DPF3a-HEY interactions.
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Figure 3. DPF3a S348 phosphorylation is important for cardiac hypertrophy. (A) NPPA and DPF3amRNA expression was analyzed in human-induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) after phenylephrine (PE) or endothelin 1 (ET-1) treatment for 24 h. (B) Immunoblotting anal-
ysis of the pDPF3a protein level with anti-pDPF3a antibody in ET-1 induced hypertrophic hiPSC-CMs. (C) The protein level of pDPF3a was analyzed in
the hearts of patients with hypertrophic cardiomyopathy (HCM) and aortic stenosis (AS). (D) Immunofluorescence of paraffin-embedded right ventricular
biopsies of normal hearts (NH) and Tetralogy of Fallot (TOF) individuals. Red: pDPF3a; green: Troponin I (TnI); arrow: pDPF3a positive cardiomy-
ocytes; arrow with tail: pDPF3a negative cardiomyocytes. Scale bar, 25 m. (E) siRNA knockdown of DPF3 followed by ET-1 treatment in hiPCS-CMs.
Expression of NPPA after DPF3 siRNA knockdown and ET-1 treatment was analyzed by qPCR. (F) Mouse primary cardiomyocytes were transfected
with either Flag-tagged DPF3a WT or S348A constructs. Cells were then stained with antibody against Flag (red), and antibody against Actinin (green).
Scale bar, 10 m. (G) The surface areas of transfected cells were measured using ImageJ (n = 20, **P < 0.01, t-test). (H) The mRNA expression of the
hypertrophic marker Nppa was analyzed by qPCR in the transfected mouse primary cardiomyocytes.
We further identified common targets of Dpf3a andHey1
using ChIP-qPCR experiments in C2C12 cells (Supple-
mentary Figure S7A), in which Hey1 is highly expressed
in contrast to almost no expression of Hey2 and Heyl
(Supplementary Figure S7B). These results indicate that
Dpf3a might indirectly bind DNA via its interaction with
the DNA-binding transcriptional repressor Hey1 in C2C12
cells. To confirm this hypothesis, we performed siRNA
knockdown of Hey1 in C2C12 cells, which resulted in a
notable reduction of Hey1 expression on mRNA and pro-
tein level (Figure 4B). Inhibition of Hey1 did not cause ex-
pression alterations ofHey2 orHeyl (SupplementaryFigure
S6B). We checked Dpf3a binding in the Hey1 knockdown
situation and found a striking reduction of Dpf3a enrich-
ment at selected targets (Figure 4, C and D). In line with
this, we also analyzed Hey1 enrichment at these targets in
a Dpf3a knockdown (Supplementary Figure S7C) situation
inC2C12 cells and observed no significant changes ofHey1-
DNA binding (Supplementary Figure S7D and E). These
results underline thatHey1 indeed serves as a linker between
Dpf3a and DNA.
Since posttranslational modifications like phosphoryla-
tion can modulate the nature and strength of protein–
protein interactions, we aimed to elucidate the protein do-
main of DPF3a required for the interaction withHEY1 and
investigated whether this interaction depends on the phos-
phorylation state of DPF3a. We assumed that the DPF3a-
HEY1 interaction is mediated by the DPF3a specific half
PHD and/or C-terminus, as we did not observe an inter-
action between DPF3b and HEY1 (Supplementary Figure
S6, B and C). Using CoIP analysis, we found that lacking
the half PHD finger prevents the interaction of DPF3a with
HEY1, confirming this hypothesis (Figure 4E).
Furthermore, we analyzed whether DPF3a phosphory-
lation affects its interaction with HEY1. We performed
CoIP analysis of HEY1 with DPF3a followed by in vitro
de-phosphorylation of the CoIP pellet using FastAP alka-
line phosphatase. Immunoblotting analysis showed that de-
phosphorylation of the DPF3a-HEY1 complex abolished
their interaction (Figure 4F). Finally, we co-transfected
HA-tagged HEY1 with Flag-tagged WTDPF3a, S348A or
5xAlamutant intoHEK293 cells. Similar expression ofWT,
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Figure 4. HEY protein links DPF3a to DNA. (A) DPF3a specifically interacts with HEY1. HEK293 cells were transiently transfected with Flag-tagged
DPF3a and with HA-tagged MYOD1, HAND1, HES1 or HEY1. Cell lysates were incubated with an anti-HA matrix or anti-Flag matrix to pull down
HA-tagged or Flag-tagged protein together with interacting proteins, which were further probed with anti-Flag or anti-HA antibody in immunoblots. (B)
C2C12 cells were transfected with Hey1 siRNA for 48 h and knockdown efficiency of Hey1 in C2C12 cells was analyzed by qPCR and immunoblotting.
(C and D) Dpf3a ChIP experiments were performed and Dpf3a enrichment at selected promoters in siHey1 knockdown was compared to siNon control.
Binding of Dpf3a was quantified by qPCR (triplicate experiments, **P < 0.01, t-test). (E) The interaction of DPF3a and HEY1 is mediated via the half
PHD finger. Co-immunoprecipitation (CoIP) of HA-tagged HEY1 with different Flag-tagged DPF3a constructs (WT, aa1–246, aa1–292 and aa292–357)
from lysates of transiently transfected HEK293 cells. (F) CoIP of Flag-tagged DPF3a and HA-tagged HEY1 followed by de-phosphorylation assay using
FastAP Alkaline phosphatase. S: supernatant. (G) Phosphorylation of serine 348 of DPF3a is critical for the interaction with HEY1. CoIP of HA-tagged
HEY1 with Flag-tagged DPF3a mutants (WT, S348A, 5xAla). (H) Quantification of the DPF3a and HEY1 interaction using Image Lab 5.0 (triplicate
experiments, **P < 0.01, t-test).
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S348A and 5xAla DPF3a protein levels were detected (Fig-
ure 4G, lane 1, 4, 7). We found that WT DPF3a efficiently
interacted with HEY1 (Figure 4G, lane 3), but the S348A
and 5xAla mutants showed a strikingly decreased interac-
tion (Figure 4G, lane 6, 9, Figure 4H). These results sug-
gest that the S348 phosphorylation is critical for theDPF3a-
HEY1 interaction mediated by the half PHD finger.
DPF3a recruits BRG1 to genomic targets
Previous work has shown that both DPF3a and DPF3b
are in a complex with the BAF chromatin remodeling com-
plex and interact with other BAF components like BRG1
and BAF60c (20,37). To determine whether HEY1 inter-
acts with any other BAF components or whether its inter-
action with DPF3a is independent of the BAF complex, we
performed CoIP assays. We did not find any interaction be-
tween HEY1 and BRG1 or BAF60c (Figure 5A, lane 2, 4).
However, HEY1, DPF3a and BRG1 formed a complex in
theCoIP assay (Figure 5A, lane 3). Thus, our results suggest
that HEY1 is associated with the BAF complex via DPF3a
and the interaction between DPF3a and HEY1 is indepen-
dent of the BAF complex.
To confirm this hypothesis, we performed ChIP-qPCR in
order to identify common Brg1-Dpf3a-Hey1 targets in WT
C2C12 and after Hey1 knockdown and found a comple-
mentary reduction of Brg1 binding to Dpf3a-Hey1 target
sites (Figure 5, B and C). Moreover, we observed a reduc-
tion of Brg1 binding at respective targets sites in the Dpf3a
knockdown condition (Figure 5, D and E). Taken together,
these results indicate that the Dpf3a-Hey1 complex directs
theBAF chromatin remodeling complex to specific genomic
target sites.
DPF3a releases HEY from the genomic targets
To examine the role of DPF3a in transcriptional activation,
HEK293 cells were co-transfected with an expression vec-
tor encoding DPF3 protein fragments fused to the GAL4
binding domain and a reporter vector containing theGAL4
promoter linked to the firefly luciferase gene. Only DPF3a,
but not DPF3b, showed transactivation activity, which is
transmitted by the DPF3a specific C-terminus (aa291–357)
(Figure 6A). This underlines a role of DPF3a in the tran-
scriptional activation.
Previous studies showed that HEY proteins function as
direct transcriptional repressors and a number of HEY tar-
get genes involved in cardiac hypertrophy have been identi-
fied previously (38–41). In our reporter gene assays, HEY1
significantly repressed the promoter activity of its target
genes like NPPA, GATA4, HEY1 and JAG1 (Figure 6B).
DPF3a alone had no impact on the promoter activity of
these target genes. Subsequently, co-transfection of reporter
constructs with HEY1 and DPF3a expression vectors re-
vealed no suppression of transcriptional activities of these
targets. DPF3a notably reduced the repression of HEY1
targets (Figure 6B), suggesting that DPF3a might release
HEY1 from DNA via a protein–protein interaction. In ad-
dition to this, mutation of the HEY1 binding E-box el-
ement (gggCACGGGtca to gggCAtca) in the JAG1 pro-
moter abolished the repression by HEY1.
Furthermore, we analyzed the expression of HEY1 and
HEY2 genes in hypertrophic hearts of patients with AS
and HCM, in which DPF3a was found to be up-regulated.
We did not observe any obvious alteration of the ex-
pression of the HEY genes (Supplementary Figure S8).
However,DPF3a-HEY1 targets, including the hypertrophic
markerNPPA aswell asFOXO1 (forkhead boxO1),GATA4
(GATA binding protein 4), TBX3 (T-box 3) and SMAD7
(SMAD family member 7), were found to be significantly
up-regulated (Figure 6C).
Model of the CK2-DPF3a-HEY-BRG1 pathway
Finally, we developed a model summarizing our findings
(Figure 7). Upon hypertrophic stimuli, the protein kinase
CK2 phosphorylates DPF3a at the highly conserved amino
acid S348 at its C-terminus. pDPF3a binds and releases the
transcriptional repressors HEY and recruits BRG1 to re-
spective targets. Consequently, DPF3a initiates transcrip-
tion of fetal genes and promotes pathological cardiac hy-
pertrophy.
DISCUSSION
Wepresent a novel pathway driving pathological cardiac hy-
pertrophy in response to hypertrophic stimuli. This pathway
is triggered by kinase activation leading to phosphorylation
of a BAF chromatin remodeling factor and consequently
triggering the release of DNA-binding transcriptional re-
pressors. In the past, reports have demonstrated the impact
of individual components, namely CK2, BRG1 and HEY,
involved in the process of cardiac hypertrophy. However,
their connection through the chromatin remodeler DPF3a
had not yet been elucidated.
The SWI/SNF chromatin remodeling complexes are re-
cruited to numerous genomic target sites by sequence-
specific transcription factors and histone-binding epige-
netic regulators (42). Each SWI/SNF complex utilizes ei-
ther BRG1 or BRM as alternative subunits with DNA-
dependent ATPase activity. The non-catalytic subunits of
SWI/SNF are often referred to as BAFs (BRG1 or BRM
associated factors). With respect to cardiac diseases, sev-
eral BAFs (BAF60c, BAF45c2/DPF3b) have been identi-
fied to play a role in the development of congenital struc-
tural heart diseases. BAF60c mediates its function by the
interaction with DNA-binding transcription factors such
as TBX5, GATA4, MYOD or SIX4, which are essential
for cardiac and muscle development (16,18,43). Another
mode of functional transition is the binding to specific hi-
stone modifications, as in case of DPF3b (20). Either way,
these BAFs promote gene transcription through their as-
sociation with BRG1, which is highly expressed in the de-
veloping heart. In contrast, in the adult heart BRM rep-
resents the prominent catalytic unit; however, upon hyper-
trophic stimuli cardiomyocytes switch to a fetal-like state
and BRG1 is reactivated as the catalytic unit (14,44). It had
been shown that BRG1 is up-regulated in patients with hy-
pertrophic cardiomyopathy and, moreover, forms a com-
plex with PARPs and several HDACs to induce the fetal
gene program in transverse aortic constriction-bandedmice
(14). In line with this, Brg1 null mice show significantly re-
duced hypertrophic response upon TAC-binding compared
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Figure 5. DPF3a recruits BRG1 to DNA via interaction with HEY. (A) HEY1 specifically interacts with DPF3a and associates with the BAF complex
via this interaction. CoIP of HA-tagged HEY1 with Flag-tagged DPF3a, BAF60c and BRG1 constructs from lysates of transiently transfected HEK293
cells. (B and C) Brg1 ChIP experiments were performed and Brg1 enrichment at selected promoters in siHey1 knockdown was compared to siNon control.
Binding of Brg1 was quantified by qPCR (triplicate experiments, **P< 0.01, t-test). (D and E) Brg1 enrichment at selected promoters in siHey1 knockdown
was compared to siNon control. Binding of Brg1 was quantified by ChIP and real-time PCR (triplicate experiments, **P < 0.01, t-test).
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Figure 6. DPF3a releases HEY from the targets. (A) GAL4 trans-activation assays. HEK293 cells were co-transfected with an expression vector encoding
DPF3 protein fragments fused to the GAL4 binding domain and a reporter vector containing the GAL4 promoter linked to the firefly luciferase gene.
Luciferase activity was normalized to renilla luciferase activity. One representative experiment performed in triplicates is shown. (B) DPF3a significantly
reduces HEY1 mediated repression. HEK293 cells were transiently transfected with NPPA, GATA4, HEY1, JAG1 and JAG1-mut reporter constructs in
the presence of empty control vector alone,HEY1 expression vector,DPF3a expression vector orHEY1 andDPF3a in combination. The results represent
the average of three independent experiments (**P < 0.01, t-test). (C) Expression analysis of FOXO1, GATA4, TBX3 and SMAD7 in AS, HCM and NH
using qPCR. Results represent median expression levels with 25% and 75% quartiles. Statistically significant differences were analyzed using a two-sided
Student t-test (*P < 0.05, **P < 0.01).
Figure 7. Illustration of pDPF3a mediated regulation of HEY-target genes. Hypertrophic signals stimulate CK2, which phosphorylates DPF3a at S348.
Phosphorylation of DPF3a enhances its ability to bind the transcription repressors HEY. Subsequently, DPF3a releases HEY from the genomic targets
and the transcription is then activated by the transcriptional machinery complex (TMC).
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to WTmice (14). However, it was unclear how BRG1 is tar-
geted to genes of the fetal gene program in this setting. Our
data suggest that DPF3a functions as the mediator to di-
rect BRG1 to fetal genes that are repressed by HEY pro-
teins in a WT adult stage but are re-expressed upon hy-
pertrophic stimuli. Moreover, we show that the binding of
DPF3a to HEY proteins is significantly enhanced by phos-
phorylation of S348, located in an evolutionary conserved
and DPF3a-specific C-terminal domain. The phosphoryla-
tion level of DPF3a is significantly higher in hypertrophic
states (e.g. ET-1 treated hiPSC-CMs or hypertrophic TOF
hearts). This phosphorylation of DPF3a is mediated by
CK2. Previously it had been shown that signaling of hy-
pertrophic stimuli (e.g. PE) can be mediated by CK2, in-
volving its two catalytic subunits CK2 and CK2’. CK2
was shown to phosphorylate and thereby activate HDAC2,
which results in the repression of anti-hypertrophic genes
(9). CK2’ was shown to induce cardiac hypertrophy via
interacting with the anti-hypertrophic cell cycle regulator
p27 (7). Insights into the down-stream mediators, namely
chromatin or transcription factors, and a potential role of
DPF3a await elucidation.
In general, protein phosphorylation is a key event in reg-
ulating protein localization, activity and protein–protein
interactions (45,46). We found that pDPF3a is predomi-
nately located in the nucleus. It had previously been shown
that CK2 translocates from the cytoplasm to the nucleus
(9), where it is suggested to phosphorylate DPF3a. How-
ever, this needs further investigation, as a non-pDPF3a spe-
cific antibody is currently lacking.Moreover, the conforma-
tional change of DPF3a upon phosphorylation awaits fur-
ther analysis. Frequently, phosphorylation occurs within an
interaction domain and thereby directly affects the bind-
ing energy (45). However, the interaction of DPF3a with
HEY proteins is mediated by its half PHD finger, whereas
S348 phosphorylation is located in the structurally unsolved
neighboring C-terminus. It is very likely that a conforma-
tional change through allosteric mechanisms affects the
DPF3a-HEY interaction.
In patients with pathological cardiac hypertrophy suffer-
ing from aortic stenosis or hypertrophic cardiomyopathy,
we observed a significant up-regulation of common DPF3a
and HEY targets, such as GATA4, FOXO1, SMAD7 and
TBX3. These genes play well-known roles in cardiac devel-
opment and disease (47–50). For instance, GATA4 regu-
lates cardiac fetal genes (51) and stress-induced cardiac hy-
pertrophy in vivo (52). Activation of FOXO1 is an important
mediator of cardiac hypertrophy (53).
In the future, it will be of interest to study the devel-
opment of pathological hypertrophy in a respective mouse
model. So far, we have generated a Dpf3tm1sper knockout
mouse, which is viable and fertile (data not shown), and can
undergo TAC-banding in order to study its hypertrophic re-
sponse. In this study, we observed that knockdown ofDPF3
buffered the ET-1 induced hypertrophy in hiPSC-CMs. It
might be that a reduction of hypertrophy in the knockout
compared to the WT mouse will be observed. An essential
aspect for these experiments is that, within the D4 protein
family, the protein domains of Dpf3a involved in the novel
pathway described here are unique for Dpf3a. In contrast,
all Dpf3b domains are highly conserved within the D4 fam-
ily, consisting of neural expressedDpf1 and ubiquitously ex-
pressed Dpf2. Thus, other D4 family members most likely
balance the physiological role of Dpf3 during development.
A number of HEY mouse models have been established
(40,54). Interestingly,HEY2 knockout mice on a mixed ge-
netic background develop cardiomyopathy with cardiac hy-
pertrophy (55). Moreover, overexpression of HEY2 in the
myocardium prevents PE-induced cardiac hypertrophy in
vivo and in vitro (56). The anti-hypertrophic function of
HEY2 is most likely mediated by the inhibition of fetal
genes likeNppa andGata4. Ourmodel suggests that DPF3a
induces pathological cardiac hypertrophy by the release of
HEY from these genes. It had been shown that members
of the HEY protein family (HEY1, HEY2, HEYL) share
genomic targets and perform similar functions (41). More-
over, we show that all three HEY proteins physically bind
to DPF3a. Thus, DPF3a can be considered as a cofactor of
HEY proteins in order to regulate cardiac gene expression.
Taken together, we provide evidence for a novel path-
way involved in the development of pathological cardiac
hypertrophy. The latter can occur primarily in cases of hy-
pertrophic cardiomyopathy or Tetralogy of Fallot or sec-
ondary, due to pressure overload like in cases of aortic
stenosis or hypertension. Pathological cardiac hypertrophy
leads to remodeling of the ventricular chambers and even-
tually heart failure. Thus, pharmacological inhibition of
hypertrophic cardiomyocyte growth has been a long-term
therapeutic goal for the treatment of heart failure. Future
studies are needed to explore the potential of the pathway
presented to be targeted for pharmaceutical interventions.
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